Highlights:
Buyers of NHS-facing healthcare businesses often focus on how long contract revenue can be relied upon, as renewal decisions sit with commissioners.
Earn-outs tied to NHS revenue growth move commissioning risk from buyer to seller and should be priced accordingly or resisted.
Self-funded mobilisation leaves EBITDA untouched but can reduce the seller's proceeds through the equity bridge.
Well-evidenced employer-funded and private revenue reduces a buyer's exposure to commissioning decisions.
Much of this can be addressed before a sale, starting with a clear view of discretionary revenue, renewal terms and contracts due within eighteen months.
Independent healthcare providers have become a fixture of NHS delivery, and that position shapes how they are valued in a sale. When a material share of a provider's revenue comes from NHS contracts, buyers focus closely on how long that revenue can be relied upon, because the contracts are awarded and renewed on decisions made outside the business. That uncertainty is reflected in more than the headline multiple. It shapes how much of the price is deferred through an earn-out, how the cost of mobilising new NHS contracts is treated in the equity bridge, and how NHS income is weighed against employer-funded and private work in the payer mix. Providers that understand how buyers approach each of these are better placed to evidence their value when a process begins.
Why buyers scrutinise NHS contract revenue
The scale of independent provision is well established. The Department of Health and Social Care expects around 35% of the diagnostic capacity the NHS requires between 2026/27 and 2028/29 — roughly two million additional tests — to come from the independent sector. The Independent Healthcare Providers Network already puts the sector's contribution at care equivalent to about twenty acute trusts, with more than a million patients removed from NHS waiting lists each year.
What a buyer looks to establish is whether a particular business will keep its share of that work. NHS contracts are awarded by commissioners, the NHS bodies responsible for buying healthcare services, and their decisions to renew a contract, re-tender it or favour NHS providers are made on their own timetable. Diligence therefore focuses on contract duration, renewal history and notice provisions, along with the proportion of revenue resting on discretionary commissioning decisions rather than statutory obligation. Without a prepared answer, the buyer supplies their own, and usually assumes the less favourable case.
How earn-outs shift commissioning risk to the seller
The uncertainty from contract revenue often finds its way into deal structure. A large proportion of lower mid-market healthcare transactions defer part of the price against performance over two or three years. In an NHS-facing business that window will typically cover contract renewals, re-tendering rounds, and shifts in commissioning priorities.
Where the earn-out is tied to growth in NHS revenue, the deferred part of the price is only paid if that revenue reaches agreed targets within the earn-out period, and whether it does depends heavily on commissioners. A contract re-tendered and awarded elsewhere, renewed at lower volumes or delayed while a commissioner reviews its priorities can put a target out of reach, however well the business delivers the services it holds. Neither the founder nor the buyer controls those decisions, but the structure determines who bears their cost. By deferring the price against NHS growth, the buyer has declined to pay upfront for revenue it cannot be sure of, and a founder who accepts that structure takes on the risk in the buyer's place. An earn-out of that kind should be reflected in the price, through a higher total consideration or a larger share paid on completion, or resisted. Accepted at face value, it leaves part of the founder's proceeds resting on commissioning decisions rather than on how the business performs.
Mobilisation costs and the equity bridge
The second pressure point sits in the balance sheet. Mobilisation is the work required to stand up a new contract before it generates income, covering recruitment, training, equipment and systems. Providers seeking NHS partnerships should expect to fund the cost of that change themselves.
Capital advanced in this way doesn’t appear in EBITDA, so the headline valuation is left untouched. It surfaces instead in the equity bridge — the calculation that converts enterprise value into the price paid for the shares after adjusting for debt, cash and working capital. Mobilisation spend shows up there as working capital absorption, and as accrued income (revenue earned but not yet invoiced), which a buyer may decline to fund. The multiple holds while the amount reaching the seller shrinks, which is why self-funded mobilisation is best treated as a financing decision with a return requirement, and documented as one. A clear record of what was invested, against which contract and when it is expected to be recovered gives the seller a basis to negotiate how that capital is treated in the equity bridge, rather than leaving the buyer to deduct it as a cost of taking on the business.
Payer mix as a valuation variable
Payer mix (the share of revenue that comes from each type of funder) determines how much of a business's income a buyer sees as exposed to commissioning decisions. NHS commissioners, employers and private patients each present a different risk profile, so established income from outside the NHS gives a buyer less to discount, provided it can be evidenced.
Employer-funded work is the clearest example. Occupational health and wellbeing services are paid for by corporates buying care for their own workforce, so they carry little commissioning risk. Healthcare funding is moving from the state towards employers, and the buyer set in occupational health has become increasingly active, with recent transactions including Warburg Pincus with Health Partners, Spire with Acorn, NorthEdge with Latus, and LDC with PAM Group. For a provider running an employer-funded line alongside its NHS contracts, that income is likely to be read as the more durable part of the revenue base.
Private pay, where patients pay directly or through private medical insurance, can play a similar role. Buyers will test whether a business has built a durable private patient base through cohort data, records that track groups of patients who started in the same period to show how many return and what they spend over time. A private line opened last year with no cohort history will persuade nobody, and may draw scrutiny onto the rest of the equity story.
Providers that know their payer mix in detail, and can present each non-NHS revenue line with the history behind it, give a buyer a much clearer view of where the durable income sits. A diversified mix strengthens the valuation when every line can be evidenced, while a recent addition with little behind it can weaken the case for the whole business.
Preparing an NHS-facing business for sale
Every area a buyer examines in an NHS-facing business comes back to the same concern: how long the revenue can be relied upon. That concern shapes the price, the share of it deferred, the capital left in the business on completion and the weight given to income from outside the NHS, and much of it can be addressed long before a process begins.
Preparation starts with the contract base: establishing what proportion of revenue depends on discretionary commissioning decisions, reviewing notice provisions and renewal mechanics, and knowing which contracts fall due within the next eighteen months. Self-funded mobilisation should be documented as a financing decision, with the return it was expected to generate, and any earn-out tied to NHS revenue growth weighed against the commissioning risk it transfers. Non-NHS revenue lines need the history to support them, so a buyer can see where the more durable income sits.
None of this relies on predicting how commissioning will change. It is the work that makes a business defensible under questioning, and it leaves a buyer far fewer gaps to fill with assumptions of their own.
For a confidential discussion about how buyers are likely to assess your business, contact Tura's Healthcare & Life Sciences advisory team.
